CHENGDA PHARMA(SZ:301201) Xin Lang Cai Jing·2025-11-19 15:00Core Viewpoint - Chengda Pharmaceutical Co., Ltd. plans to utilize up to 700 million yuan of idle funds for low-risk cash management to enhance capital efficiency [1][5]. Group 1: Investment Plan - The investment will be limited to low-risk, highly liquid financial products with a maturity of no more than 12 months, including agreed deposits, notice deposits, time deposits, structured deposits, and financial institution wealth management products [2]. - The total investment limit for the company and its subsidiaries is set at 700 million yuan, which can be used cyclically within the 12-month period [2]. Group 2: Risk Control - The company has established multiple risk control mechanisms, including a dynamic tracking mechanism to monitor product allocation and project progress, internal audit supervision for regular checks on investment projects, and the option for third-party audits as needed [3]. Group 3: Impact on the Company - The cash management initiative aims to ensure normal operations and fund safety while achieving value preservation and appreciation of idle funds, ultimately creating more returns for shareholders [5]. - The 700 million yuan investment amount will be assessed against the company's latest audited cash reserves to ensure alignment with the principle of "standardized operation and prudent management" [5]. Group 4: Review Process and Sponsor Opinion - The proposal has been approved by the board's audit committee and will be submitted for shareholder approval [6]. - The sponsor, Guangda Securities Co., Ltd., has confirmed that the necessary review procedures were followed and has no objections to the cash management initiative [6].